Global Gynecology Drugs Market is Estimated to Value Over USD 5 Billion by 2026 End

  • 17 Oct 2019

Global Gynecology Drugs Market is estimated to value over USD 5 billion by 2026 end and register a CAGR of over 5.3% during the forecast period 2019 to 2026.

Gynecologic conditions act upon in the female reproductive system of the female body. The most prevalent indicators of gynecologic conditions range from vaginal itching to abnormal vaginal bleeding, pelvic pain, breast lumps, breast pain and even vaginal discharge. The gravity of these indicators are often subject to age, as these indicators may be pertinent to hormonal fluctuations which occur as one ages.

An array of gynecological conditions exist which includes sexually transmitted disease (STD) and is shown to be both prevalent as well as highly critical. Another common sexually transmitted disease that many women carry is pelvic inflammatory disease. The US region is plagued with the epidemic of more than one million women, who encounter such a condition in their lives. Chlamydia also counts as being among the serious and critical conditions. Such a disease infects the vagina and if it goes untreated, it can lead to a disease known as pelvic inflammatory disease. Sometimes, gynecological diseases can be linked to the menstrual cycle and there are chances of getting endometriosis and menstrual cramps.

It has been observed that various forms of cancer such as ovarian and endometrial cancers have witnessed an exponential rise among women. Such a high prevalence of these illnesses have played a role in increasing the global gynecology drugs market size. 

Menopause is characterized as a long-term cessation of menstruation, that comes about as a result of activity loss of ovarian follicles. This is a natural occurrence among women, who are typically around the age of 50. A vast number of women are entering menopause at an earlier than anticipated age owing to the lack of healthy diet and sufficient exercise, as well as varied environmental factors. Research has demonstrated that a staggering number of women between the ages of 45 and 65, have either experienced menopause or are expected to encounter it soon enough. Among the many detriments of menopause which many women have claimed to experience range from irritability, hot flashes, mood swings, vaginal dryness and interrupted sleep. Occurrences of menopausal vasomotor indications have seen an alarming rise in recent years and such incidents are expected to drive the global gynecology drugs market growth at a faster growth rate.

The North America region is expected to dominate the market during the forecast time frame, as there is a growing pattern of acceptance of products with technological prowess, along with a high prevalence of major players and a surge in healthcare-related expenditure. Europe is also predicted to capture a sizeable global gynecology drugs market share as a result of the growing instances of gynecological illnesses is projected to drive the market in the region during the forecast timeline. The Asia Pacific region has gained significant market traction owing to the rise of healthcare expenditure. Furthermore, a great deal of emphasis is placed on expansion to capture unexplored population pool as well as a rise in healthcare awareness which will, most likely, propel the gynecology drugs market in Asia Pacific.


Major players that have dominated the market for gynecology drugs includes F. Hoffmann-La Roche Ltd., Sanofi, Amgen Inc., GlaxoSmithKline plc, AstraZeneca, Pfizer, Inc., Lupin Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Johnson, Bayer AG, Allergan Plc and Merck & Co.


Global Gynecology Drugs Market Segmentation:

By Therapeutics

  • Hormonal Therapy

- Estrogen Therapy

- Progestin Therapy

- Combination Therapy

- Thyroid Replacement Therapy

- Parathyroid Hormone Therapy

- Others

  • Non-hormonal Therapy

- Anti-Infective Agents

- Antineoplastic Agents

- Anti-inflammatory Agents

- Others

By Indication

  •  Gynecology Cancers
  •  Endometriosis
  •  Female Infertility
  •  Menopausal Disorder
  •  Gynecology Infections
  •  Polycystic Ovary Syndrome
  •  Contraception (Birth Control)
  •  Others

By Distribution Channel

  •  Hospital Pharmacies
  •  Retail Pharmacies
  •  Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


FutureWise Key Takeaways:

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth


Objectives of the Study:

  • To provide with an exhaustive analysis on the global gynecology drugs market by therapeutics, by indication, by distribution channel and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions


Get unlimited analyst support and customise this study further to your requirements, contact